再鼎醫藥(09688.HK)與河南省腫瘤醫院達成戰略合作
再鼎醫藥(09688.HK)公布與河南省腫瘤醫院簽署戰略合作協議,雙方將在基礎研究、臨床試驗、人才培養、學術交流、科研管理、平台建設等領域合作,深化「院企合作」模式,促進科研成果轉化,提升腫瘤防治能力。
鼎醫藥首席商務官兼大中華區總裁梁怡表示,河南省腫瘤醫院臨床業務規模及研究實力為全國前列,截至目前醫院承接各期藥物臨床試驗逾600項,未來將合作研發腫瘤創新藥。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.